ZA202100718B - Antibody molecules that bind cd137 and ox40 - Google Patents
Antibody molecules that bind cd137 and ox40Info
- Publication number
- ZA202100718B ZA202100718B ZA2021/00718A ZA202100718A ZA202100718B ZA 202100718 B ZA202100718 B ZA 202100718B ZA 2021/00718 A ZA2021/00718 A ZA 2021/00718A ZA 202100718 A ZA202100718 A ZA 202100718A ZA 202100718 B ZA202100718 B ZA 202100718B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibody molecules
- bind
- binding site
- antibody
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811407.4A GB201811407D0 (en) | 2018-07-12 | 2018-07-12 | Antibody molecules that bind CD137 and OX40 |
| GBGB1818281.6A GB201818281D0 (en) | 2018-11-09 | 2018-11-09 | Antibody molecules that bind CD137 and OX40 |
| GBGB1902598.0A GB201902598D0 (en) | 2019-02-26 | 2019-02-26 | Antibody molecules that bind cd137 and ox40 |
| PCT/EP2019/068796 WO2020011966A1 (en) | 2018-07-12 | 2019-07-12 | Antibody molecules that bind cd137 and ox40 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202100718B true ZA202100718B (en) | 2025-07-30 |
Family
ID=67383740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/00718A ZA202100718B (en) | 2018-07-12 | 2021-02-02 | Antibody molecules that bind cd137 and ox40 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12252537B2 (https=) |
| EP (1) | EP3820898B1 (https=) |
| JP (2) | JP7397055B2 (https=) |
| KR (1) | KR20210031479A (https=) |
| CN (1) | CN112424229B (https=) |
| AU (1) | AU2019301206B2 (https=) |
| BR (1) | BR112021000282A2 (https=) |
| CA (1) | CA3106048A1 (https=) |
| ES (1) | ES3044118T3 (https=) |
| IL (1) | IL280002B2 (https=) |
| MX (1) | MX2021000399A (https=) |
| SG (1) | SG11202100172XA (https=) |
| TW (1) | TWI847989B (https=) |
| WO (1) | WO2020011966A1 (https=) |
| ZA (1) | ZA202100718B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EP3728316B1 (en) | 2017-12-19 | 2025-02-26 | invoX Pharma Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| CN112585165B8 (zh) | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| PT3820569T (pt) | 2018-07-12 | 2025-01-14 | Invox Pharma Ltd | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| NZ787680A (en) | 2019-10-24 | 2026-02-27 | Cedars Sinai Medical Center | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| WO2022178114A1 (en) * | 2021-02-17 | 2022-08-25 | Aptevo Research And Development Llc | Compositions comprising 4-1bb and ox40 binding proteins and methods of use |
| AU2022262542A1 (en) * | 2021-04-22 | 2023-11-02 | Astellas Pharma Inc. | Anti-cldn4/anti-cd137 bispecific antibody |
| CN114478771B (zh) * | 2021-12-14 | 2024-06-25 | 英诺湖医药(杭州)有限公司 | Ox40抗体及其医药用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| EP4600651A1 (en) * | 2024-02-06 | 2025-08-13 | Consiglio Nazionale Delle Ricerche - CNR | Method for diagnosing coeliac disease |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| EP4686882A1 (en) | 2024-07-31 | 2026-02-04 | BDR Thermea Group B.V. | System to prevent frost damage to an outdoor heating appliance |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2245404C3 (de) | 1972-09-15 | 1978-08-31 | Robert Bosch Gmbh, 7000 Stuttgart | Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben |
| JPS531908B2 (https=) | 1973-11-12 | 1978-01-23 | ||
| JPS5746634B2 (https=) | 1974-05-10 | 1982-10-04 | ||
| JPS5146628A (ja) | 1974-10-17 | 1976-04-21 | Nippon Denso Co | Teikoirisupaakupuragu |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP1025230B1 (en) | 1997-12-01 | 2006-02-08 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
| DE19818214A1 (de) | 1998-04-24 | 1999-10-28 | Bosch Gmbh Robert | Zündkerze für eine Brennkraftmaschine |
| EP2011801A1 (en) | 1999-05-27 | 2009-01-07 | Government of the United States as represented by the Secretary, Department of Health and Human Services | Immunoconjugates having high binding affinity |
| JP4578025B2 (ja) | 2001-07-06 | 2010-11-10 | 日本特殊陶業株式会社 | スパークプラグ |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP1699826B1 (en) | 2005-01-05 | 2009-03-11 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| EP2399935A3 (en) | 2005-02-15 | 2012-02-22 | GTC Biotherapeutics, Inc. | An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| EP1861425B1 (en) | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| ES2627223T3 (es) | 2007-06-26 | 2017-07-27 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Presentación de agentes de unión |
| MX2010005603A (es) | 2007-11-26 | 2010-08-02 | Bayer Schering Pharma Ag | Anticuerpos antimesotelina y usos de los mismos. |
| PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| RU2531754C2 (ru) | 2008-04-11 | 2014-10-27 | ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US | Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010057047A1 (en) | 2008-11-13 | 2010-05-20 | Trubion Pharmaceutics, Inc. | Cd37 immunotherapeutic combination therapies and uses thereof |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2411416A1 (en) | 2009-03-24 | 2012-02-01 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Anti-mesothelin antibodies |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| BR112013014527A2 (pt) | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| JP5276742B1 (ja) | 2012-08-09 | 2013-08-28 | 日本特殊陶業株式会社 | 点火プラグ |
| CN104955845B (zh) | 2012-09-27 | 2018-11-16 | 美国政府(由卫生和人类服务部的部长所代表) | 间皮素抗体和引起有效的抗肿瘤活性的方法 |
| EP3508215A3 (en) | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| US11634502B2 (en) | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| US10344088B2 (en) | 2013-03-15 | 2019-07-09 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| GB201317622D0 (en) | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
| US10899840B2 (en) | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| JP5902757B2 (ja) | 2014-06-24 | 2016-04-13 | 日本特殊陶業株式会社 | スパークプラグ |
| WO2015198312A1 (en) | 2014-06-24 | 2015-12-30 | Ccam Therapeutics Ltd. | Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| WO2016025379A1 (en) | 2014-08-10 | 2016-02-18 | Federal-Mogul Ignition Company | Spark plug with improved seal |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| KR20180016972A (ko) | 2015-02-22 | 2018-02-20 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd137에 결합하는 항체 치료제 |
| TW201642897A (zh) | 2015-04-08 | 2016-12-16 | Ｆ 星生物科技有限公司 | Ｈｅｒ２結合劑治療 |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| CN114181309B (zh) * | 2015-05-21 | 2024-07-30 | 鳄鱼生物科学公司 | 新型多肽 |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| JP6025921B1 (ja) | 2015-06-22 | 2016-11-16 | 日本特殊陶業株式会社 | スパークプラグ |
| WO2017009456A1 (en) | 2015-07-15 | 2017-01-19 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for lag-3 |
| CN114853891A (zh) | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| CA2994631A1 (en) | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
| JP6845846B6 (ja) | 2015-09-22 | 2021-04-21 | ディンフー バイオターゲット カンパニー リミテッド | 抗ヒトｃｄ１３７の完全ヒト抗体及びその用途 |
| KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| US10526413B2 (en) | 2015-10-02 | 2020-01-07 | Hoffmann-La Roche Inc. | Bispecific antibodies specific for OX40 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| GB201519481D0 (en) * | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| IL300122A (en) | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| US20190330336A1 (en) | 2015-11-19 | 2019-10-31 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| KR20180096789A (ko) | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| JP6365802B2 (ja) | 2016-03-18 | 2018-08-01 | 大日本印刷株式会社 | 中間転写媒体と熱転写シートとの組合せ、及び印画物の形成方法 |
| EP3445788B1 (en) | 2016-04-22 | 2022-01-19 | Alligator Bioscience AB | Novel bispecific polypeptides against cd137 |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| BR112018074453A2 (pt) | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
| US20190106494A1 (en) | 2016-06-13 | 2019-04-11 | Askgene Pharma Inc. | PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis |
| HRP20210602T1 (hr) | 2016-06-20 | 2021-05-14 | F-Star Delta Limited | Vezujuće molekule koje vežu pd-l1 i lag-3 |
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN107523546A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的nk细胞及其用途 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| CN109715666B (zh) | 2016-07-20 | 2023-02-21 | 斯特库比股份有限公司 | 癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法 |
| ES2981272T3 (es) | 2016-09-23 | 2024-10-08 | Merus Nv | Moléculas de unión que modulan una actividad biológica expresada por una célula |
| GB201616699D0 (en) | 2016-09-30 | 2016-11-16 | Mab Designs Ltd | Antibodies |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| WO2018115859A1 (en) | 2016-12-20 | 2018-06-28 | Kymab Limited | Multispecific antibody with combination therapy for immuno-oncology |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| US11260117B2 (en) | 2017-05-26 | 2022-03-01 | Novimmune Sa | Anti-CD47 x anti-mesothelin antibodies and methods of use thereof |
| JP2020522495A (ja) | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| EP3728316B1 (en) | 2017-12-19 | 2025-02-26 | invoX Pharma Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| PT3820569T (pt) | 2018-07-12 | 2025-01-14 | Invox Pharma Ltd | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| AU2020275209A1 (en) | 2019-05-14 | 2021-12-23 | F-Star Therapeutics Limited | Dosage regimes for the administration of a LAG-3/PD-L1 bispecific antibody |
-
2019
- 2019-07-12 ES ES19742152T patent/ES3044118T3/es active Active
- 2019-07-12 BR BR112021000282-0A patent/BR112021000282A2/pt unknown
- 2019-07-12 JP JP2021500295A patent/JP7397055B2/ja active Active
- 2019-07-12 IL IL280002A patent/IL280002B2/en unknown
- 2019-07-12 SG SG11202100172XA patent/SG11202100172XA/en unknown
- 2019-07-12 TW TW108124753A patent/TWI847989B/zh active
- 2019-07-12 MX MX2021000399A patent/MX2021000399A/es unknown
- 2019-07-12 WO PCT/EP2019/068796 patent/WO2020011966A1/en not_active Ceased
- 2019-07-12 EP EP19742152.2A patent/EP3820898B1/en active Active
- 2019-07-12 CA CA3106048A patent/CA3106048A1/en active Pending
- 2019-07-12 CN CN201980046865.2A patent/CN112424229B/zh active Active
- 2019-07-12 KR KR1020217003610A patent/KR20210031479A/ko not_active Ceased
- 2019-07-12 US US17/259,796 patent/US12252537B2/en active Active
- 2019-07-12 AU AU2019301206A patent/AU2019301206B2/en active Active
-
2021
- 2021-02-02 ZA ZA2021/00718A patent/ZA202100718B/en unknown
-
2023
- 2023-11-30 JP JP2023202717A patent/JP7701964B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3106048A1 (en) | 2020-01-16 |
| IL280002B2 (en) | 2025-05-01 |
| EP3820898B1 (en) | 2025-09-03 |
| AU2019301206B2 (en) | 2025-10-30 |
| JP7701964B2 (ja) | 2025-07-02 |
| EP3820898A1 (en) | 2021-05-19 |
| KR20210031479A (ko) | 2021-03-19 |
| JP7397055B2 (ja) | 2023-12-12 |
| ES3044118T3 (en) | 2025-11-26 |
| JP2024019415A (ja) | 2024-02-09 |
| CN112424229B (zh) | 2024-07-30 |
| BR112021000282A2 (pt) | 2021-04-06 |
| SG11202100172XA (en) | 2021-02-25 |
| TWI847989B (zh) | 2024-07-11 |
| TW202019963A (zh) | 2020-06-01 |
| JP2021524267A (ja) | 2021-09-13 |
| IL280002B1 (en) | 2025-01-01 |
| US20220048996A1 (en) | 2022-02-17 |
| MX2021000399A (es) | 2021-05-27 |
| US12252537B2 (en) | 2025-03-18 |
| WO2020011966A1 (en) | 2020-01-16 |
| CN112424229A (zh) | 2021-02-26 |
| AU2019301206A1 (en) | 2021-03-04 |
| IL280002A (en) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100718B (en) | Antibody molecules that bind cd137 and ox40 | |
| EP4512417A3 (en) | Antibody molecules that bind pd-l1 and cd137 | |
| ZA202007570B (en) | Mesothelin and cd137 binding molecules | |
| ZA202100723B (en) | Fc binding fragments comprising a cd137 antigen-binding site | |
| CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| MX2022014463A (es) | Construcciones de union a antigeno para moleculas diana. | |
| MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
| PH12021550662A1 (en) | Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously | |
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
| PH12021551487A1 (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| EA202191176A1 (ru) | Поливалентные модуляторы регуляторных т-клеток | |
| EP4556020A3 (en) | Antibody molecules | |
| EA201070695A1 (ru) | Молекулы гуманизированных антител, специфичных к il-31 | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| EA201690447A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ | |
| EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
| MX2021014193A (es) | Moleculas de enlace biespecificas anti-ror1/anti-cd3. | |
| EA202092605A1 (ru) | Антитела к ил-11ra | |
| MX2024005841A (es) | Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias. | |
| JOP20210085A1 (ar) | أجسام مضادة لـ TNF- alpha وشظايا وظيفية منها |